A Search Service for Abbreviation / Long Form

â–  Abbreviation / Long Form : ED / extensive disease

[Related PubMed/MEDLINE]
Total Number of Papers: 208
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ED  (>> Co-occurring Abbreviation)
Long Form:   extensive disease
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 The prognostic role of PET/CT in small-cell lung cancer. 18F FDG, LD, MTV, OS, PET/CT, PFS, SCLC, TLG
2020 Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study. CIs, LD, OS, PDCT, PFS, SCLC
2019 A Case of Long-term Survival of 36 Months in the Setting of Extensive-disease Small-cell Lung Cancer. NCCN, PCI, SCLC
2019 A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. ORR, OS, PD-L1, PFS, PR, SCLC
2019 Curative thoraco-systemic therapy plus local treatment to the brain for extensive disease-small-cell lung cancer with metastasis only to the brain. LD
2019 Decreased Levels of Histidine-Rich Glycoprotein in Advanced Lung Cancer: Association with Prothrombotic Alterations. CLT, HRG, LC
2019 DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. DDR, DSB, HR, LD, SSB, TMB
2019 Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer. DLT, LD, MTD, PS, TRT
2019 Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia. AE, CI, CRP, IP, LDH, OS, SCLC
10  2019 Modified Glasgow Prognostic Score as a Prognostic Factor in Patients with Extensive Disease-Small-Cell Lung Cancer: A Retrospective Study in a Single Institute. mGPS, OS, SCLC
11  2019 Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer. ---
12  2019 Radiotherapy for small cell carcinoma of the esophagus: outcomes and prognostic factors from a retrospective study. ECOG PS, LD, OS, SCCE
13  2019 The efficacy of amrubicin third-line chemotherapy in patients with relapsed extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute. CI, DCR, OS, SCLC
14  2018 A lower level of forced expiratory volume in one second predicts the poor prognosis of small cell lung cancer. COPD, FEV1, HR, OS, PFT, SCLC
15  2018 Efficacy and safety of amrubicin-based regimen used as first-line for extensive-disease small-cell lung cancer: A meta-analysis of randomized controlled trials. CIs, HR, ORR, OS, PFS, RCTs, RR, SCLC
16  2018 Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer. NSCLC, SCLC
17  2017 Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. OS, SCLC
18  2017 Neuroendocrine carcinoma of the esophagus: Clinicopathological and immunohistochemical features of 14 cases. LD, NEC
19  2017 Nine-year Experience: Prophylactic Cranial Irradiation in Extensive Disease Small-cell LungCancer. EORTC, MRI, OS, PCI, SCLC
20  2017 Paraneoplastic limbic encephalitis in a patient with extensive disease small-cell lung cancer. PLE, SCLC, VPA
21  2017 The Humanistic Burden of Small Cell Lung Cancer (SCLC): A Systematic Review of Health-Related Quality of Life (HRQoL) Literature. HRQoL, PROs, SCLC
22  2016 Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer. LD, NSCLC, ROC, SCLC
23  2016 Clinical features and prognostic factors of small cell lung cancer: A retrospective study in 148 patients. LD, MST, OS, SCLC
24  2016 Extrapulmonary small cell carcinoma of lymph node: Pooled analysis of all reported cases. LD, LNEPSCC
25  2016 Human Epididymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer. HE4, LD, SCLC
26  2016 Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort. BM, LD, LDH, NSCLC, SCLC, SREs
27  2016 Mediastinal small cell carcinoma: a unique clinical entity? EPSCCs, LD, MSCC, MST, SCC
28  2016 The Younger Patients Have More Better Prognosis in Limited Disease Small Cell Lung Cancer. ECOG, LD, OS, PCI, PS, SCLC
29  2016 Treatment for small cell lung cancer, where are we now?-a review. CNS, LD, LS, PCI, SCLC
30  2016 [Utility of NSE, ProGRP and LDH in Diagnosis and Treatment
in Patients with Small Cell Lung Cancer]. LD, LDH, NSE, PFS, ProGRP, SCLC
31  2015 Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer. CI, LD, SCLC
32  2015 Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide. EC, EP, LD, LRC, OS, SCLC
33  2015 Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience. ACO, LD, OS
34  2015 The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer. CI, FGFR1, HR, OS, PFS, SCLC
35  2014 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis. CI, CT, F-FDG, SCLC
36  2014 Chemotherapy with cisplatin or carboplatin in combination with etoposide for small-cell esophageal cancer: a systemic analysis of case series. EP/CP, LD, MST, SCEC
37  2014 Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution. JCO, LD, OS, PFS, RR, SCLC
38  2014 Extrapulmonary small cell carcinoma: the University of Kansas experience and review of literature. LD, PS
39  2014 Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus. CI, IP, NEC, OS, PFS
40  2014 Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. AP, HR, IP, OS, SCLC
41  2014 Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer. CT, FDG, LD, MTV, PET, SCLC, TLG
42  2014 Retrospective review of extra-pulmonary small cell carcinoma and prognostic factors. EPSCC, LD, OS
43  2013 "EXHALE": exercise as a strategy for rehabilitation in advanced stage lung cancer patients: a randomized clinical trial comparing the effects of 12weeks supervised exercise intervention versus usual care for advanced stage lung cancer patients. NSCLC, SCLC
44  2013 Clinical characteristics and outcomes of patients with small cell lung cancer detected by CT screening. CT, LD, MST, SCLC
45  2013 Clinical management of small-cell carcinoma of the urinary tract: a 10-year single-center's experience. LD, NSE, OS, PFS, SCC, SCCUT
46  2013 New dilemmas in small-cell lung cancer TNM clinical staging. LD, SCLC, TNM
47  2013 [Present role of prophylactic cranial irradiation]. BM, LD, NSCLC, PCI, SCLC
48  2012 Hyponatremia as prognostic factor in small cell lung cancer--a retrospective single institution analysis. LD, SCLC
49  2012 Hypoxia-inducible factor-1alpha and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study. ERCC1, HIF-1alpha, SCLC
50  2012 Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients. CHT, LD, s.c, SSTRS
51  2012 Management of small cell lung cancer: recent developments for optimal care. LD, QOL, SCLC
52  2012 Non-surgical approach to small cell carcinoma of the esophagus: does this rare disease have the same tumor behavior as SCLC? LD, SCEC, SCLC
53  2012 Prognostic role of integrin beta1, E-cadherin, and rac1 expression in small cell lung cancer. E-cad, ECM, LD, OS, PFS, SCLC
54  2012 Prophylactic cranial irradiation for small-cell lung cancer: how, when and for whom? LD, NT, PCI, SCLC
55  2012 [Clinical manifestation and radiological features of small cell lung cancer (SCLC)]. SCLC
56  2011 Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer. FDG-PET, LD, SCLC, TLG
57  2011 Mediastinal radiotherapy after multidrug chemotherapy and prophylactic cranial irradiation in patients with SCLC--treatment results after long-term follow-up and literature overview. LD, PCI, SCLC
58  2011 Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer. LD, SCLC
59  2011 Prognosis of small-cell lung cancer since the introduction of amrubicin. AMR, LD, MST, SCLC
60  2011 Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. iSUV, LD, MTV, OS, PFS, SCLC
61  2011 Prophylactic cranial irradiation in lung cancer. LD, PCI
62  2011 Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. CI, ORR, PS, SCLC
63  2011 [Analysis of treatment outcomes in two patient cohorts (2004-2005 and 2007-2008) with limited and extensive disease small-cell lung cancer]. LD, SCLC
64  2010 A 20-year retrospective study of small-cell carcinomas in Taiwan. LD, SCC
65  2010 High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. LD, OS, SCLC
66  2010 Impact of 18F-fluorodeoxyglucose positron emission tomography in the staging and treatment response assessment of extra-pulmonary small-cell cancer. EPSCC, FDG, LD, PET, RT
67  2010 Prognostic factors in small cell lung cancer: a new prognostic index in Korean patients. LD, MST, OS, SCLC
68  2010 Retrospective review of extra-pulmonary small cell carcinoma at King Chulalongkorn memorial hospital cases during 1998-2005. EPSCC, LD
69  2010 Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: The Netherlands Cancer Institute experience and literature review. LD, PCI, SCBC
70  2010 [Treatment and prognosis of extrapulmonary small cell carcinoma of 243 cases]. EPSCC, LD
71  2009 A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer. AUC, DLT, SCLC
72  2009 Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer. MSTs, ORR, SCLC
73  2009 High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. LD, SCLC
74  2009 Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer. CI, IGFBP-3, IGFR-1, LDH, OS, PFS, SCLC
75  2009 [Treatment and prognosis of primary esophageal small cell carcinoma: a report of 151 cases]. LD, PESC
76  2008 Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study. LD, OS, PCR
77  2008 Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. CR, EC, IC, OS, PS, QOL, SCLC
78  2008 Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. LD, SCLC
79  2008 Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. GE, LD, SCC
80  2007 Extrapulmonary small cell carcinoma: single center experience with 61 patients. EPSCC, GI, LD, OS, SCC
81  2007 Survival of small-cell lung cancer and its determinants of outcome in Singapore. LD, SCLC
82  2007 [Lung cancer in patients with chronic renal failure]. LD, NSCLC, SCLC
83  2006 A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer. G-CSF, LD, PS, SCLC
84  2006 A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. AUC, SCLC
85  2006 A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer. LD, MTD, SCLC
86  2006 Extrapulmonary small cell cancer: a Canadian province's experience. EPSCC, LD, OR, SCC
87  2006 Extrapulmonary small cell carcinoma--a medical center's experience. CR, DFS, EP, EPSCC, LD, OS, PR
88  2006 Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer. CI, CR, LD, PD, PR, PS, SCLC, SD
89  2006 [Extrapulmonary small cell carcinoma in 52 patients]. ESCC, LD, MST
90  2005 Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group. SCLC
91  2005 Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. LD
92  2005 Therapy, outcome and analysis of c-kit expression in patients with extrapulmonary small cell carcinoma. CT, EPSCC, LD
93  2004 Extrapulmonary small-cell carcinoma: a single-institution experience. EPSCC, LD, OS, SCC
94  2004 Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. BM, LD, SCLC, SIADH
95  2003 Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer. CR, ECOG, IVE, LD, OR, PR, SCLC
96  2003 Detection of occult tumor cells in peripheral blood from patients with small cell lung cancer by promoter methylation and silencing of the retinoic acid receptor-beta. LD, PMNC, RARbeta, SCLC
97  2003 Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group. SCLC, TTP
98  2003 Progress in treatment of small-cell lung cancer: role of CPT-11. LD, SCLC
99  2002 Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. CEV, EP, LD, SCLC
100  2002 High-dose chemotherapy in small-cell lung cancer. ABMT, CR, ICE, LD, PBPC, SCLC